{"title":"质子束治疗","authors":"Jason Lester","doi":"10.17925/EOH.2018.14.2.82","DOIUrl":null,"url":null,"abstract":"POLICY Group 1: Proton Beam Therapy (PBT) is considered medically necessary for the curative treatment of any of the following: Chordomas and chondrosarcomas of the base of the skull, localized and in the postoperative setting Uveal melanoma, when PBT is considered preferential compared to brachytherapy Select cases of localized unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (see discussion in Key Clinical Points) Stage IIA seminoma Malignancies requiring Craniospinal Irradiation (CSI)","PeriodicalId":38554,"journal":{"name":"European Oncology and Haematology","volume":"42 1","pages":"82"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proton Beam Therapy\",\"authors\":\"Jason Lester\",\"doi\":\"10.17925/EOH.2018.14.2.82\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"POLICY Group 1: Proton Beam Therapy (PBT) is considered medically necessary for the curative treatment of any of the following: Chordomas and chondrosarcomas of the base of the skull, localized and in the postoperative setting Uveal melanoma, when PBT is considered preferential compared to brachytherapy Select cases of localized unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (see discussion in Key Clinical Points) Stage IIA seminoma Malignancies requiring Craniospinal Irradiation (CSI)\",\"PeriodicalId\":38554,\"journal\":{\"name\":\"European Oncology and Haematology\",\"volume\":\"42 1\",\"pages\":\"82\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Oncology and Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/EOH.2018.14.2.82\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Oncology and Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EOH.2018.14.2.82","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
POLICY Group 1: Proton Beam Therapy (PBT) is considered medically necessary for the curative treatment of any of the following: Chordomas and chondrosarcomas of the base of the skull, localized and in the postoperative setting Uveal melanoma, when PBT is considered preferential compared to brachytherapy Select cases of localized unresectable hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (see discussion in Key Clinical Points) Stage IIA seminoma Malignancies requiring Craniospinal Irradiation (CSI)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
